Member Info for Wildforce

When scib1 or scib2 goes into trial with keytruda .. there will be side effects .. here's some numbers from that trial ! "The safety of KEYTRUDA was consistent with what has been seen in previous trials among patients with metastatic NSCLC. Grade 3-5 adverse events from any cause occurred in 67.2 percent of patients in the KEYTRUDA plus pemetrexed and platinum chemotherapy group and 65.8 percent in the chemotherapy alone arm. " Can immunobody improve this risk !? Time will tell ., Take care all ..

I always did like mk3475 eh !! Now it just needs to find safer combo partners that raise specific t-cell avidity dependent on target indication! Hartlepool won !!!! Rooting for your guys too !! Come on you Gulls !!! Take care ..

For these treatments, which turn up the heat on tumours, there needs to be an at least partly in-tact immune system .. A system where there are t-cells available via dendritic cells to be 'programmed' ... Once that system is compromised these mechanisms won't work anyway ... LD has recognised this and hence the collaboration with BioNTech into the TCR space using the Moditope targeting of stressed cells to overcome the lack of any immune capability ! Patient selection is critical when running these trials... And that depends on the understanding of your product ! Better selection ... Smaller and shorter trials.. Knowledge first ... Trials second .. There is no rushing this process ! It's not easy curing cancer ! [all my opinion of course] Dyor as ever ... Take care all ..

That is worth noting indeed !! I'd not connected it though ! LD has done her homework it seems ! Thanks ! I thought those checkmate numbers although promising, have left a lot of room for improvement still ! Take care ..

Remembering immunobody is not restricted to accessible tumours... https://www.fiercebiotech.com/biotech/checkmate-s-i-o-combo-reverses-pd-1-resistance-melanoma-patients Turning the heat up on cancer is becoming a hot topic !! Take care all ..

Is great when global leaders get together .. cruk, aacr and sclp ! (I added sclp using a bit of poetic licence)! http://www.cancerresearchuk.org/about-us/cancer-news/press-release/2018-04-16-two-global-cancer-leaders-announce-ambitious-strategic-alliance Take care all ..

Just catching up on the day ... Brilliant and very welcome news ! Keep punching ... Fingers crossed you'll be fit enough to get to the AGM later this year ! Would be great to catch up again ! Take care ..

Bear in mind ..all stage 3 patients , and time to primary endpoint .. https://www.medscape.com/viewarticle/895204 Take care all ..

With such well accomplished professionals clearly impressed with scancell's science ... does that not help give anyone holding between 1 and 7 million shares enormous confidence that their own research has been 'on the money' ... the markets will follow.... sometime ? Buy and hold ? Not advice ... my opinion! Take care all..

Wrong board .. Sorry all .. Meant to be on sclp Great rns here by the way .. Take care all ..

Early detection - early treatment .. The way forward .. Late stage treatment a very competitive arena that will suffer hugely as earlier interventions become more effective as more is understood about the immune system .. I know where my money is .. Oncosec .. Will always be confined to late stage arena. Take care .. The uk is getting its act together ! Slowly ..

Good luck to HIO and all who sail with her !!

Bearing in mind Bluerose claims to have no interest in SCLP - check out his/her profile .... something fishy going on with bluerose ..... Take care all - my one and only post here , good luck all !!

Apart from sclp, sclp and sclp ..... I'll go very high risk and go PXS, THR , GPRT !! Ouch !!